QA102 Phase II Study in Subjects With Dry AMD

Summary

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

Timeline

Start

2022-09-22

Primary completion

2024-11-12

Completion

2024-11-12

Drugs

Indications